IBI3005 / Innovent Biologics - LARVOL DELTA

Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=282 | Not yet recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

New P1/2 trial • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • ROS1

Study of IBI3005 in Subjects with Unresectable, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=198 | Recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Trial completion date: Jun 2027 ➔ Dec 2027 | Initiation date: Jun 2024 ➔ Jan 2025 | Not yet recruiting ➔ Recruiting

Enrollment open • Trial completion date • Trial initiation date • Oncology • Solid Tumor

Article 2: Innovent Biologics' first dual-antibody ADC approved for clinical trials in China [Google translation] (Sohu.com) - "On December 20, the CDE official website showed that Innovent Biologics' IBI3005 was approved for clinical trials. This is the first time that IBI3005 has been approved for clinical trials in China."

New trial • Oncology • Solid Tumor

Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=198 | Not yet recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor